Results 41 to 50 of about 4,216 (212)

Information on the combined hormonal contraceptives (CHC) containing the dienogest + ethinyl estradiol combination (Jeanine®)

Акушерство, гинекология и репродукция, 2019
In this short communication, the editorial board publishes the information on safety of the combined hormonal contraceptive (CHC) Jeanine®, containing the fixed dose combination of dienogest and ethinyl estradiol.
A. D. Makatsariya, V. O. Bitsadze, D. V. Blinov, D. I. Korabelnikov   +3 more
doaj   +1 more source

Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase III, Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To compare the efficacy, safety and tolerability of elagolix with dienogest in women with moderate‐to‐severe endometriosis‐associated pain. Design A multicentre, double‐blind, double‐dummy, randomised, parallel‐group, active‐controlled, non‐inferiority phase III study. Setting Nineteen clinical centres across India.
Sneha Bhoir, Jaldhara Patel, Tushar Palve, Mrinal Kanti Dash, Sweety Saigal, Gourisankar Kamilya, Shalini Srivastava, Kartikbhai Savalia, Tanusree Gupta, Deepa Choudhary, Manohar Rangaswamy, Vidya V Bhatt, Neena Gupta, Malathi Ponnuru, Parul Shah, Apurva Shetty, Shruti Saha, Reshma Quadros, Sucheta Pandit, Dipak Patil, Piyush Patel, Pravin Ghadge, Lalit Lakhwani, Suyog Mehta, Sadhana Joglekar   +24 more
wiley   +1 more source

Efficacy of 0.5 mg Dienogest Tablets in Treating Premenstrual Syndrome-like Symptoms: A Comparative Study with a Low-Dose Estrogen–Progestin Combination

Endocrines
Dysmenorrhea treatment with 0.5 mg dienogest tablets twice daily (1 mg/day) has proven useful, but its effect on premenstrual disorders has not yet been evaluated.
Haruko Yokosuka
doaj   +1 more source

Estetrol‐based combined oral contraceptives: A systematic review of clinical outcomes

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
This systematic review summarizes clinical outcomes of estetrol‐containing combined oral contraceptives, showing reliable contraceptive efficacy, predictable bleeding patterns, improved well‐being, and a favorable hemostatic and metabolic profile, suggesting a promising and potentially safer alternative to ethinylestradiol‐based formulations.
Mathilde Råberg, Ingeborg Rose Vad, Kara Hildur Axelsdóttir, Ellen Christine Leth Løkkegaard   +3 more
wiley   +1 more source

Impact of combined oral contraceptives and progestin‐only pills on psychological and sexual well‐being of women with endometriosis: A systematic review

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 5, Page 805-818, May 2026.
Hormonal treatments for endometriosis (combined oral contraceptives/progestin‐only pills) do not show increased psychological or sexual risks compared with placebo. When pain is effectively controlled, these therapies appear well tolerated and may improve overall well‐being.
Noemi Salmeri, Martina Piccini, Francesca Caprara, Edgardo Somigliana, Paola Viganò, Paolo Vercellini   +5 more
wiley   +1 more source

Single‐Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non‐Pregnant, Non‐Lactating Premenopausal Female Subjects Under Fasting Conditions

Clinical Pharmacology in Drug Development, Volume 15, Issue 4, April 2026.
Abstract Elagolix is a short‐acting oral gonadotropin‐releasing hormone antagonist utilized for treating endometriosis‐associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use in Indian women remain limited.
Sudershan Kumar, Arshad Khuroo, Reshma Quadros, Shruti Dharmadhikari, Chintan Khandhedia, Gaurav Puppalwar, Amey Mane   +6 more
wiley   +1 more source

Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. [PDF]

, 2014
Endometriosis, a leading cause of pelvic pain and infertility, is characterized by ectopic growth of endometrial-like tissue and affects approximately 176 million women worldwide. The pathophysiology involves inflammatory and angiogenic mediators as well
Canny, G.O., Clerc, A.C., Golshayan, D., Gori, I., Govender, L., Kumar, R., Pellegrini, C., Russell, R., Wyss, J.C.   +8 more
core   +2 more sources

Three‐dimensional patient‐derived endometriosis model for drug evaluation

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 4, Page 629-646, April 2026.
In this study, we developed a coculturing model with stromal cells and epithelial organoids to mimic the endometriotic lesion and for further evaluation of drug effects. Abstract Introduction Endometriomsis (EMs) is a complex and chronic gynecological disease characterized by distressing symptoms.
Yuqi Li, Wei Shao, Xiaoxiao Gao, Yongxing Wang, Jinzhi Li, Liansuo Zhang, Yanyan Xing, Wentao Su, Yan Cheng, Li Wang, Songping Liu   +10 more
wiley   +1 more source

New ways in therapy of abnormal uterine bleedings related to adenomyosis [PDF]

Гинекология, 2015
The purpose of research was a comparison of the effect of a three-phase combined oral contraceptive (COC) containing estradiol valerate and dienogest in dynamic mode and single agent containing dienogest, to reduce menstrual blood loss on the background ...
N N Rukhliada, E I Biriukova, M A Melnikova, D M Gasimova   +3 more
doaj  

Abdominal-pelvic pain in female patients with endometriosis - a review of the literature [PDF]

, 2018
Abdominal-pelvic pain is the dominant symptom in endometriosis, one of the most common pathologies that affect women, being also a multifactorial disorder.
Andronache, Liliana Florina, Badiu, Cristinel Dumitru, Grigorean, Valentin Titus, Mandu, Mihaela, Mastalier, Bogdan, Mehedintu, Claudia, Paduraru, Dan Nicolae, Pantea Stoian, Anca Mihaela, Sima, Marina Romina   +8 more
core   +1 more source